Study finds adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence
The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only ...
Forbes8y
Encouraging Results For Ribociclib In Advanced Breast Cancer
At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...
Trading Sat17d
Novartis : Annonce la recommandation du ribociclib
(CercleFinance.com) - Le ribociclib (Kisqali®) de Novartis est reconnu comme traitement adjuvant privilégié de catégorie 1 pour le cancer du sein par les directives de pratique clinique en ...
University of Sheffield2y
Breast cancer – Ribociclib
Ribociclib in combination with an aromatose inhibitor for previously untreated advanced or metastatic hormone receptor-positive, her2-negative breast cancer. The NICE appraisal committee wanted to ...
Pharmabiz16d
Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines
This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...
Indiatimes1mon
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...